

Anticoagulants
and Fibrinolysins

The Ontario Heart Foundation and
The Faculty of Medicine, University of Toronto

INTERNATIONAL SYMPOSIUM

Anticoagulants
and
Fibrinolysins

Edited by

R. L. MacMillan and J. F. Mustard

London

Pitman Medical Publishing Co. Ltd.

COPYRIGHT © 1961
by the Ontario Heart Foundation

Published in Great Britain by
PITMAN MEDICAL PUBLISHING CO. LTD.
39 Parker St., London, W.C.2

Printed in Canada

Anticoagulants
and
Fibrinolysins

THE SYMPOSIUM WAS HELD IN
TORONTO, CANADA, FEBRUARY 2, 3, & 4, 1961
UNDER THE AUSPICES OF

THE ONTARIO HEART FOUNDATION

JOHN S. DINNICK — President

JOHN HAMILTON — Chairman Medical Committee

M. ROBERTSON — Executive Director

THE FACULTY OF MEDICINE UNIVERSITY OF TORONTO

J. A. MACFARLANE — Dean of Medicine

IAN MACDONALD — Director of Post Graduate Medical Education

SYMPOSIUM COMMITTEE

K. W. G. BROWN

W. F. CONNELL

R. L. MACMILLAN

F. C. MONKHOUSE

J. F. MUSTARD — Chairman

Participants

NAME	POSITION	DEPARTMENT	SCHOOL OR UNIVERSITY
Alkjaersig, Norma K. M.S.	Research Assistant Professor of Medicine	Dept. of Medicine	Washington University School of Medicine St. Louis
Ambrus, Julian L. M.D., Ph.D.	Principal Cancer Research Scientist	Dept. of Health, State of New York	Roswell Park Memorial Institute Buffalo
Arnott, W. Melville M.D.	Professor	Dept. of Medicine	Queen Elizabeth Hospital Birmingham
Ashwin, James G. Ph.D.	Research Associate	Dept. of Physi- ology & Pharmacology	University of Saskatchewan Saskatoon
Astrup, Tage Ph.D.	Director of Research	James F. Mitchell Foundation	Washington Clinic Washington
Berman, Herbert, J. Ph.D.	Research Associate	Dept. of Biology	Graduate School Boston University Boston
Best, Charles H.	Director of Research	Banting - Best Department of Medical Research	University of Toronto Toronto
Biggs, Rosemary M.D., Ph.D.	Scientific Officer to M. R. C.	Blood Coagula- tion Research Unit	Churchill Hospital Oxford
Bjerkelund, C. J. M.D.	Associate Clinical Professor	Dept. of Medicine Ullevaal Hospital	Oslo University Oslo
Borchgrevink, C. F. M.D.	Research Fellow	Institute for Thrombosis Research	University Hospital Oslo
Brinkhous, Kenneth M. M.D.	Professor	Dept. of Pathology	University of North Carolina Chapel Hill
Brown, K. W. G. M.D.	Associate	Dept. of Medicine	University of Toronto Toronto

Carleton, Richard A. M.D.	Research Assistant	Dept. of Cardiology	U.S. Naval School of Aviation Medicine Pensacola
Clifton, Eugene E. M.D.	Associate Member	Dept. of Surgery	Sloan-Kettering Institute for Cancer Research New York
Connell, W. Ford M.D.	Professor	Dept. of Medicine	Queen's University Kingston
Groch, Sigmund N. M.D.	Assistant Professor	Dept. of Medicine	Cornell University New York
Hamilton, John, D. M.D.	Dean	Faculty of Medicine	University of Toronto Toronto
Hartert, H. M.D.	Associate Professor	Dept. of Medicine	University Hospital of Heidelberg Heidelberg
Horlick, L. M.D.	Associate Professor	Dept. of Medicine	University of Saskatchewan Saskatoon
Jaques, Louis B. Ph.D.	Professor	Dept. of Phys- iology & Pharmacology	University of Saskatchewan Saskatoon
Johnson, Shirley A. Ph.D.	Assistant Professor	Dept. of Physiology	Marquette University College of Medicine Milwaukee
Kline, Daniel L. Ph.D.	Professor	Dept. of Physiology	Yale University School of Medicine New Haven
Knisely, Melvin H. Ph.D.	Professor	Dept. of Anatomy	Medical College of South Carolina Charleston
Lorand, L. Ph.D.	Associate Professor	Dept. of Chemistry	Northwestern University Evanston
Manchester, Benjamin M.D.	Assistant Clinical Professor	Dept. of Medicine	George Washington University Washington
Markus, Gabor M.D., Ph.D.	Established Investigator of the American Heart Association	Dept. of Health State of New York	Roswell Park Memorial Institute Buffalo
Marshall, J. M.D.	Reader in Clinical Neurology	Dept. of Neurology	National Hospital for Nervous Diseases London
Mayer, George A. M.D.	Lecturer in Medicine	Dept. of Medicine	Queen's University Kingston

McDevitt, Ellen M.D.	Assistant Professor	Dept. of Medicine	Columbia University New York
McDonald, Lawson M.D.	Assistant Director	Institute of Cardiology	National Heart Hospital London
Meyer, J. S. M.D.	Professor	Dept. of Neurology	Wayne State University Detroit
Monkhouse, F.C. Ph.D.	Professor	Dept. of Physiology	University of Toronto Toronto
More, Robert H. M.D.	Professor	Dept. of Pathology	Queen's University Kingston
Murphy, Edmund A. M.D.	Instructor	Dept. of Medicine	Johns Hopkins University Baltimore
Nichol, E. Sterling		Blood Coagula- tion Research Unit	University of Miami Miami
Olwin, John H. M.D.	Clinical Associate Professor	Dept. of Surgery	University of Illinois Chicago
Owren, Paul A. M.D.	Professor	Dept. of Medicine	University Hospital Oslo
Painter, Robert H. Ph.D.	Research Associate	Connaught Medical Research Laboratories	University of Toronto Toronto
Quick, Armand J. M.D. Ph.D.	Professor	Dept. of Biochemistry	Marquette University School of Medicine Milwaukee
Robertson, H. Roche	Professor	Dept. of Surgery	McGill University Montreal
Seegers, Walter H. Ph.D.	Professor	Dept. of Phys- iology & Pharmacology	Wayne State University Detroit
Sise, Herbert S. M.D.	Assistant Clinical Professor	Dept. of Medicine	Tufts University School of Medicine Boston
Soulier, J. P. M.D.	Director	Centre National de Transfusion Sanguine	Paris
Steeves, Lea C. M.D.	Associate Professor	Dept. of Medicine	Dalhousie University Halifax
Storrie, V. Marie M.D.	Assistant	Dept. of Medicine	University of Winnipeg Winnipeg
Wessler, Stanford M.D.	Assistant Professor	Dept. of Medicine	Harvard University Boston
Wightman, K. J. R.	Professor	Dept. of Medicine	University of Toronto Toronto

Discussants

H. J. M. Barnett	Toronto, Ontario
Paul David	Montreal, Quebec
Alick Little	Toronto, Ontario
Louis Lowenstein	Montreal, Quebec
Harry Shanoff	Toronto, Ontario
Shepard Shapiro	New York, New York
L. DeWitt Wilcox	London, Ontario

Preface

The prevention of myocardial and cerebral infarction is one of the major problems facing the physician today. Of the measures available for the prevention of thrombosis associated with arterial disease, anticoagulant therapy has seemed the most promising. While the success of anticoagulants in the treatment of venous thrombosis appears to be established, the evidence for benefit in arterial disease is less conclusive. Arterial thrombosis differs from venous thrombosis in that the arterial wall is usually damaged by atheroma and blood flow is rapid and pulsatile. These and other factors may account for some of the difficulty in determining the value of anticoagulant therapy in the prevention of arterial thrombi.

This symposium, held in Toronto in February, 1961, was to a large extent devoted to the problem of arterial thrombosis. Particular attention was given to recent developments in basic knowledge of the etiology and prevention of thrombosis. The practical aspects of anticoagulant therapy were discussed and with this combined approach it was hoped that a better understanding of the usefulness of anticoagulant therapy would be possible. It was decided to include a special section on fibrinolysins because of their potential value in the management of acute thrombosis.

This book contains the papers given at the symposium and the discussions which followed them. The editors would like to thank the participants for their co-operation in forwarding their manuscripts so promptly. We are indebted to the Ontario Heart Foundation for sponsoring the symposium and in particular to Mr. Murray Robertson and his staff for helping in the preparation of the discussions and manuscripts for publication. The publication of this volume is due to the efforts of Mr. R. J. Blacker, President of the Hunter Rose Company Limited and the publisher, The Macmillan Company of Canada Limited.

R. L. MacMillan

J. F. Mustard

Toronto, Ontario

March, 1961

Introduction

The idea that a Conference on Anticoagulants should be held arose in the Medical Committee of the Ontario Heart Foundation some years ago because of conflicting results reported by grantees in different centres. The Chairman at that time, Dr. Hurst Brown, suggested that it would be of value to have a meeting in Toronto of the individuals involved to try to clarify the problem. The original concept soon grew beyond a meeting of local groups because it was felt that with such a limited number of participants the objectives would not be realized, that is, a fuller understanding of the whole problem of Anticoagulant therapy. Discussions with those working in the field soon led to the proposal for a meeting that would be international in scope and would cover all aspects of the problems of blood coagulation and its modification by therapeutic means. A local Committee under the chairmanship of Dr. Fraser Mustard and including Dr. K.G.W. Brown, Dr. R.L. MacMillan, Dr. F.C. Monkhouse and Dr. W. Ford Connell then considered how best this might be arranged and came forward with a plan for a symposium on Anticoagulants and Fibrinolysins. The Board of Directors of the Ontario Heart Foundation supported their recommendations in the belief that a symposium would advance our knowledge in a field that was of vital importance in cardiovascular disease.

The success of the venture is evident in the high calibre of the contributions in this book. What is not evident here but was appreciated by all the participants was the opportunity for individual discussion. These conversations I am sure played just as important a role as the formal presentations in the dissemination of knowledge.

On behalf of the Foundation, I wish to express our appreciation to the contributors and participants in the symposium, to Dr. Mustard and his Committee for the organization of the program, and to Mr. Murray Robertson and his staff for the excellent arrangements for the meeting and the social functions.

John Hamilton

Contents

PARTICIPANTS	xi
DISCUSSANTS	xiv
PREFACE	xv
INTRODUCTION John D. Hamilton	xvii
A SHORT ESSAY ON THE HISTORY OF ANTICOAGULANTS Charles H. Best	1
I BASIC MECHANISMS OF COAGULATION	
Chairman: Charles H. Best	
1. Prothrombin as an Example of the Selective Differentiation of a Protein Molecule Walter H. Seegers	11
2. The Formation of Plasma Thromboplastin and the Assay of Specific Coagulation Factors Rosemary Biggs	20
3. "Paradoxical" Thrombosis and Haemorrhage (Penick's Syndrome). Some Intermediary Sequences in Its Pathogenesis Kenneth M. Brinkhous	28
4. Anticoagulant Activity of Circulating Blood F. C. Monkhouse	35
Discussion	42
II THE EFFECT OF ANTICOAGULANTS ON BLOOD COAGULATION	
Chairman: Walter H. Seegers	
5. The Changes in the Blood Coagulation Mechanisms Wrought by the Administration of the Oral Anticoagulants Shirley A. Johnson	47
6. The Adhesive Index, a Measure of Platelet Stickiness. Its Response to Myocardial Injury and to Anticoagulant Treatment Louis Horlick	56
7. The Effects of Dicumarol and Heparin Therapy on Platelet Economy. The Relationship of These Changes to Thrombus Formation Edmund A. Murphy	68

8.	The Relation of Dicumarol and Heparin to Haemostasis Louis B. Jaques	77
9.	Effects of Heparin on Blood Coagulation and Thrombosis in Ischaemic Heart Disease Lawson McDonald	86
	Discussion	92
I	THROMBOGENESIS - Part One Chairman: John D. Hamilton	
10.	Anticoagulant-induced Alterations in Haemostasis, Platelet Thrombosis, and Vascular Fragility in the Peripheral Vessels of the Hamster Cheek Pouch Herbert J. Berman	95
11.	Factors Involved in the Initiation of Thrombosis Stanford Wessler	108
12.	The Effect of Drugs on Experimental Thrombogenesis James G. Ashwin	117
13.	Long-term Anticoagulant Therapy in Angina Pectoris; the Therapeutic Level of Long-term Anticoagulant Treatment Chr. F. Borchgrevink	128
14.	Heparin Therapy following Acute Myocardial Infarction Richard A. Carleton	133
	Discussion	138
	THROMBOGENESIS - Part Two Chairman: H. Rocke Robertson	
15.	The Role of Thrombosis in Occlusive Disease of Coronary Arteries Robert H. More	143
16.	Thrombolytic Treatment in Cerebrovascular Thrombosis J.S. Meyer	154
17.	Differences in Thrombus Formation and Composition Melvin H. Knisely	165
	Discussion	173
IV	CONTROL OF AND CRITERIA FOR ADEQUATE ANTICOAGULANT THERAPY Chairman: W. Melville Arnott	
18.	The One-stage Prothrombin Time Armand J. Quick	177
19.	Methods for Controlling Anticoagulant Therapy Paul A. Owren	187
20.	The Heparin Tolerance Test in the Control of Anticoagulant Therapy J.P. Soulier	195

21.	Dicumarol Resistance J. P. Soulier	201
22.	Standard Clotting Time in the Control of Adequate Anti- coagulant Therapy George A. Mayer	204
23.	Comparison of the Standard Clotting Time with the Prothrom- bin Time Lea C. Steeves	211
	Discussion	217
V CHOICE OF ANTICOAGULANT AND COMPLICATIONS		
	Chairman: E. Sterling Nichol	
24.	Some Problems in Controlling Long-term Anticoagulation Herbert S. Sise	225
25.	Complications of Anticoagulant Therapy - Methods of Prevention Ellen McDevitt	236
26.	The Choice of Anticoagulant Drugs - Adequate Anticoagulant Therapy John H. Olwin	240
	Discussion	254
VI CLINICAL APPLICATIONS - Part One		
	Chairman: K. J. R. Wightman	
27.	Failure of Anticoagulant Prophylaxis after Myocardial Infarction K. W. G. Brown	259
28.	The Effectiveness of Anticoagulant Prophylaxis after Myo- cardial Infarction C. J. Bjerkelund	266
29.	Anticoagulant Prophylaxis following Coronary Occlusion Benjamin Manchester	276
30.	Long-term Anticoagulant Administration after Cardiac Infarc- tion W. Melville Arnott	285
31.	Failures of Long-term Anticoagulant Therapy W. Ford Connell	295
	Discussion	299
CLINICAL APPLICATIONS - Part Two		
	Chairman: Paul A. Owren	
32.	The Role of Anticoagulant Therapy in the Management of Cerebrovascular Disease John Marshall	305

33. Anticoagulant Therapy in Occlusive Cerebral Vascular Disease Sigmund N. Groch	309
34. Use of Anticoagulants in Impending Myocardial Infarction V. Marie Storrie	313
35. The Role of Heparin in the Induction of Anticoagulant Therapy W. Ford Connell	323
Discussion	329
VII FIBRINOLYSINS	
Chairman: Tage Astrup	
36. Chemical Basis of the Clotting Reaction in Blood L. Lorand	333
37. The Plasminogen Activator from Kidney Tissue Cultures Robert H. Painter	351
38. A Simplified Procedure for the Isolation of Purified Human Plasmin Daniel L. Kline	360
39. The Activation of Plasminogen <u>in Vitro</u> and <u>in Vivo</u> Norma K. Alkjaersig	365
40. On the Heterogeneity of Streptokinase-induced Plasmin Gabor Markus	376
Discussion	385
VIII CLINICAL APPLICATION OF FIBRINOLYSINS	
Chairman: J. P. Soulier	
41. Comparative Laboratory Studies on the Effect of Anticoagulants and Fibrinolytics H. Hartert	389
42. Principles of Anticoagulant and Thrombolytic Therapy Tage Astrup	394
43. Proteolytic Enzyme Inhibitors: Their Action on Blood Coagulation and Fibrinolysis J. P. Soulier	403
44. Clinical and Experimental Studies with Fibrinolytic Enzymes: a Progress Report J. L. Ambrus	413
45. Clinical Evidence for Effectiveness of Fibrinolytic Therapy in Thrombo-embolic Disease; Correlation with Animal Experiments Eugene E. Clifton	429
Discussion	431
CONFERENCE SUMMARY	433
J. F. Mustard	
INDEX	441

A Short Essay on the History of Anticoagulants

CHARLES H. BEST (Toronto)

One can say quite a lot in twenty minutes but a bit of planning is required to make the most of the opportunity. I have decided to focus your attention for two-thirds of my time on anticoagulants which have, at least experimentally, been shown to prevent thrombosis, but I will begin with the one I first used and which was generally available in physiological laboratories forty years ago, i.e., hirudin.

The date of the first use of venesection in human patients would be difficult to establish. Leeches were employed to replace venesection probably a thousand years ago and their use was widespread until the turn of the century and continues in some countries to this day. My father had them available but I never saw him use them in his medical practice. The druggist or chemist kept leeches in water in glass jars with a bit of sand in the bottom. They were not fed for months at a time but the water was changed. In the 18th century leeches were exported from Bavaria and Bohemia to France by special large "diligences"--the "leech express"! Dr. Erik Jorpes tells us that for many years in Sweden and many other European countries, apothecaries were forced, by law, to keep jars of leeches on their shelves (27). In 1884 John B. Haycraft (18), working in England and also in Strasbourg, reported that blood flow from a leech bite was not easily arrested. He noted that the blood within the body of the leech (*Hirudo medicinalis*) remained fluid indefinitely and when ejected it did not coagulate. Various experiments were undertaken to determine the source and action of the anticoagulant factor. The conclusion was reached that the leech secretes from its mouth a fluid which destroys the "blood ferment". An extract of leech heads was effective in preventing clotting of dog's or rabbit's blood but not that of Crustacea. It had no action on the curdling of milk, the clotting of myosin or in hastening rigor mortis.

Krüdger in Dorpat (34), Dickinson (15), in England, and Erick Schultze (43) of Greifswald in Germany, purified the extract of leech heads and attempted unsuccessfully to isolate the active substance. In 1902 Franz in Jacoby's laboratory in Göttingen (17) attacked the problem. Jacoby was interested in transfusions of blood and suggested to Franz that he should assay the leech extracts under standard conditions on rabbit blood and that he should then use the test as a guide in the purification of the active material. The potency of the leech extract was preserved with thymol and large quantities of stable active material were made available. A method of preparation was evolved which consisted of extracting leech heads in saline for two hours at 60°C. The liquid was centrifuged and the precipitate discarded. The clear supernatant was dried in a desiccator over sulphuric acid. A solution of the dry powder was readily made in distilled water. The active substance was not dialysable and the results of salt precipitations suggested a protein-like structure. In 1903 Professor Jacoby (24) suggested the name "Hirudin".

In 1909 my friend, the late Professor John Mellanby (31), studied the mechanism of action of hirudin and while it is frequently not profitable to attempt the interpretation of older experiments in terms of modern knowledge, it would appear from his results that hirudin contained an antithrombokinase and also an antithrombin. Since Mellanby's thrombin may well have been contaminated with kinase, some of his procedures--even in his careful and experienced hands--gave results which could be interpreted in more than one way. In addition to obtaining strong evidence that hirudin was both an antithrombin and an antikinase, Mellanby showed that fibrinogen removed hirudin from the scene of action. An earlier worker, Bodong (5) had concluded, erroneously it appears, that fibrinogen had been chemically changed by the hirudin so that its potential for fibrin formation was decreased.

Interest in hirudin has continued practically to the present time. In 1929 Waldeschmidt-Leitz, Stadler and Steigerwaldt (49) showed that the anticoagulant action of hirudin was lost during tryptic digestion. In 1957, F. Markwardt (29) of the Pharmacological Institute in Greifswald, isolated hirudin in crystalline form. It is a protein with a low molecular weight of about 16,000 as determined by osmotic pressure measurements. Chromatographic and electrophoretic studies indicate a single substance. Fifteen amino acids have been identified. There are relatively large amounts of cystine, asparagine, and glutamic acid. The substance is a potent antithrombin and has been assigned an activity of 8500 antithrombin units per mg. This would be based on the equivalent number of International Units of thrombin inactivated. The prevention of thrombosis by hirudin has not been studied and the substance has not been used in the treatment of human patients. To complete this picture the exact arrangement of the amino acids in hirudin should be determined, the protein should be synthesized and the actions of the pure product should be subjected to a comprehensive investigation by the most modern and well-established methods.

I must confine my remarks about heparin strictly to the historical aspects because we expect plenty of good-natured differences of opinion about the mechanisms of its various actions and its place in therapeutics or in the prevention of disease. There is controversy about practically all important discoveries. Many people almost made each of these advances. In some cases the claims are false; the scientific world is not convinced by others; exceptionally, the discovery is clear-cut and has been overlooked. I must not consider critically here the contributions of Schmidt in 1892 (39), or that of Doyon in 1912 (16). The latter work, had it been extended, might have anticipated the discovery of heparin by Jay McLean in Howell's laboratory in 1916 (30). There has been some controversy over the question whether the anticoagulant that McLean, Howell and Holt worked with was in fact heparin. It almost certainly was. McLean has described his vicissitudes in 1915 and 1916 when he worked on the "Thromboplastic Action of Cephalin" and "incidentally" but not "accidentally" secured evidence for the presence of a new anticoagulant in extracts of dog's liver (3). In 1918 Howell and Holt (20) wrote: "Attention was first called to this substance (heparin) during some work done in this laboratory by Jay McLean." This was the first public announcement of the discovery of heparin. The name "heparin" was introduced by Howell and Holt. In 1922 (21) and 1925 (22) Howell described the preparation of heparin in more purified form and in 1928 (19) he published a report on its chemical and physiological actions.

In 1928 I made a detailed study of the literature and it was very clear that there was little activity in the heparin field. A potent anticoagulant which could